A5093059379- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Cancer Immunotherapy and Biomarkers
- Monoclonal and Polyclonal Antibodies Research
- Viral Infectious Diseases and Gene Expression in Insects
- Erythrocyte Function and Pathophysiology
- Neuroblastoma Research and Treatments
- Glioma Diagnosis and Treatment
- 3D Printing in Biomedical Research
- Cytokine Signaling Pathways and Interactions
- Fibroblast Growth Factor Research
- T-cell and B-cell Immunology
- Phagocytosis and Immune Regulation
Research Institute of Fundamental and Clinical Immunology
2022-2024
CD 71+ erythroid nucleated cells have pronounced immunoregulatory properties in normal and pathological conditions. Many populations of with are considered candidates for cellular immunotherapy various pathologies. This study characterized the CD71+ derived from CD34-positive bone marrow under influence growth factors that stimulate differentiation into cells. CD34-negative were used to isolate nuclear The resulting assess phenotype, determine mRNA spectrum genes responsible main pathways...
Restoring immune tolerance is a promising area of therapy for autoimmune diseases. One method that helps restore immunological the approach using tolerogenic dendritic cells (tolDCs). In our study, we analyzed effectiveness transfected with DNA constructs encoding IL-10, type II collagen, and CCR9 to induce in an experimental model arthritis.
TCR-like chimeric antigen receptor (CAR-T) cell therapy has emerged as a game-changing strategy in cancer immunotherapy, offering broad spectrum of potential targets, particularly solid tumors containing intracellular antigens. In this study, we investigated the cytotoxicity and functional attributes vitro-generated T-lymphocytes, engineered with CAR precisely targeting testis MAGE-A4. Through viral transduction, T-cells were genetically modified to express co-cultured MAGE-A4-expressing...
Adoptive T-cell therapies tailored for the treatment of solid tumors encounter intricate challenges, necessitating meticulous selection specific target antigens and engineering highly receptors (TCRs). This study delves into cytotoxicity functional characteristics in vitro-cultured T-lymphocytes, equipped with a TCR designed to precisely cancer-testis antigen NY-ESO-1. Flow cytometry analysis unveiled notable increase population cells expressing activation markers upon encountering...
Introduction Adoptive cell therapy using TCR-engineered T-cells is one of the most effective strategies against tumor cells. The TCR T-cell approach has been well tested a variety blood neoplasms but yet to be deeply solid tumors. Among tumors, cancer-testis antigens are prominent targets for tumor-specific therapy, as they usually found on cells that lie behind blood-tissue barriers. Methods We have employed novel efficient protocol MAGE-A3-specific clonal expansion, performed single-cell...
The development of T cell receptor-engineered cells (TCR-T) targeting intracellular antigens is a promising strategy for treating solid tumors; however, the mechanisms underlying their effectiveness remain poorly understood. In this study, we employed advanced techniques to investigate functional state engineered with retroviral vectors express TCR specific NY-ESO-1 157-165 peptide in HLA-A*02:01 context. Flow cytometry revealed predominance naïve cells. Gene expression profiling using...
: Adoptive cell therapy is the most promising approach for battling cancer, with T receptor-engineered (TCR-T) emerging as viable option treating solid tumors. Current techniques preparing TCR-T provide a limited number of candidates TCRs, missing comprehensive view repertoire, which may hinder identification effective TCRs.
Adoptive cell therapy, particularly T receptor–engineered (TCR-T) represents a cutting-edge and promising strategy for treating solid tumors [1]. Current methods developing TCR-T therapies yield limited number of candidate TCRs [2], missing the comprehensive view repertoire, which may impede identification most effective TCRs. This limitation highlights need new techniques in therapy development.
TCR-engineered T cells targeting intracellular antigens hold promise for cancer therapy. Yet, the mechanisms driving their effectiveness remain elusive. This study employed a cutting-edge approach to explore adaptation and functional state of with TCR specific NY-ESO-1 in vivo. We revealed unique subset CD8+ effector cells, exhibiting gene expression profile characteristic both CTLs NK cells.
Фенотип и эффекторные функции GD2-специфичных CAR-T-клеток in vitro1 Федеральное государственное бюджетное научное учреждение «Научно-исследовательский институт фундаментальной клинической иммунологии» Министерства науки высшего образования Российской Федерации, 630099, г.Новосибирск, Российская Федерация 2 Университет Миэ, г.Цу, Япония Резюме Введение.Использование Т-лимфоцитов с химерным антигенным рецептором (CAR) лежит в основе новых перспективных технологий иммунотерапии опухолей, идея...
The development of T-lymphocytes with a TCR-like CAR receptor, recognizing antigens associated tumors in conjunction MHC, opens up wide range potential antigen targets various cellular localizations, particularly solid ideal intracellular antigens. In our study, we investigated the cytotoxicity and functional characteristics vitro generated receptor specific to MAGE-A4.
Introduction. Bone marrow erythroblasts produce a wide range of cytokines with opposite biological effects. This may be due to change in the spectrum production immunoregulatory mediators during differentiation and small qualitative quantitative differences produced at each stage differentiation, which important for regulation hemo- immunopoiesis. The aim. To study by different stages differentiation. Methods. Erythroblasts were obtained from CD34+ bone cells healthy donors presence...